Edwards Lifesciences

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell EW and other ETFs, options, and stocks.

About EW

Edwards Lifesciences Corp. engages in patient-focused medical innovations for heart disease and critical care monitoring. Its products are categorized into four main areas: Transcatheter Aortic Valve Replacement, Transcatheter Mitral and Tricuspid Therapies, Surgical Structural Heart, and Critical Care.

CEO

Bernard J. Zovighian

CEOBernard J. Zovighian

Employees

15,800

Employees15,800

Headquarters

Irvine, California

HeadquartersIrvine, California

Founded

1958

Founded1958

Employees

15,800

Employees15,800

EW Key Statistics

Market cap

45.52B

Market cap45.52B

Price-Earnings ratio

41.46

Price-Earnings ratio41.46

Dividend yield

—

Dividend yield—

Average volume

6.41M

Average volume6.41M

High today

$80.42

High today$80.42

Low today

$76.66

Low today$76.66

Open price

$77.20

Open price$77.20

Volume

5.39M

Volume5.39M

52 Week high

$87.89

52 Week high$87.89

52 Week low

$65.94

52 Week low$65.94

Stock Snapshot

The current Edwards Lifesciences(EW) stock price is $78.45, with a market capitalization of 45.52B. The stock trades at a price-to-earnings (P/E) ratio of 41.46.

On 2026-02-18, Edwards Lifesciences(EW) stock moved within a range of $76.66 to $80.42. With shares now at $78.45, the stock is trading +2.3% above its intraday low and -2.4% below the session's peak.

Trading volume for Edwards Lifesciences(EW) stock has reached 5.39M, versus its average volume of 6.41M.

Over the past 52 weeks, Edwards Lifesciences(EW) stock has traded between a high of $87.89 and a low of $65.94.

EW News

Simply Wall St 6d

Edwards Lifesciences Margin Compression To 17.5% Tests Premium P/E Narrative

Advertisement Edwards Lifesciences FY 2025 earnings snapshot Edwards Lifesciences (EW) has wrapped up FY 2025 with fourth quarter revenue of US$1,569.6 millio...

TipRanks 6d

Edwards Lifesciences price target lowered to $90 from $94 at UBS

UBS lowered the firm’s price target on Edwards Lifesciences (EW) to $90 from $94 and keeps a Neutral rating on the shares. Published first on TheFly – the ulti...

Simply Wall St 7d

Edwards Lifesciences Is Down 6.2% After Margin-Squeezing 2025 Results And Cautious 2026 EPS Outlook

In the past week, Edwards Lifesciences reported Q4 2025 sales of US$1,569.6 million and full-year 2025 sales of US$6.07 billion, alongside issuing 2026 guidance...

Analyst ratings

69%

of 32 ratings

Buy

68.8%

Hold

31.3%

Sell

More EW News

TipRanks 7d

Edwards Lifesciences: Sustained TAVR Momentum, Margin Upside, and New LAAC Growth Support Buy Rating

Analyst Travis Steed of Bank of America Securities reiterated a Buy rating on Edwards Lifesciences, retaining the price target of $103.00. Travis Steed has giv...

People also own

Based on the portfolios of people who own EW. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.